



# Individuals with Scientific or Medical Training - Survey Feedback

**Purpose:** This document presents feedback submitted through the 2026 survey for individuals with scientific or medical training. The table reproduces the substantive survey information provided by respondents. Survey responses reflect the experience and opinions of individual respondents and have not been independently verified by PDAB. Blank survey items are shown as “No response.”

## Verzenio (*abemaciclib*)

|                                                                                                |                                                                       |
|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Primary professional role                                                                      | Pharmacist or pharmacy professional                                   |
| Years of experience treating or studying this condition                                        | More than 10 years                                                    |
| Practice setting                                                                               | Specialty Pharmacy                                                    |
| Typical role of this drug treatment                                                            | Second-line therapy                                                   |
| Patient population most commonly receiving this drug                                           | Moderate                                                              |
| Is this drug clinically substitutable for at least one alternative?                            | Yes, for most patients                                                |
| Compared to therapeutic alternatives, this drug provides                                       | Similar benefit                                                       |
| Strength of evidence supporting use for its primary indication                                 | High (multiple RCTs, guideline-supported)                             |
| Off-label use in your practice or system                                                       | Occasional                                                            |
| Utilization management requirement typically associated with this drug (Select all that apply) | Prior authorization; Quantity limits; Specialty pharmacy requirement; |
| Administrative burden relative to alternatives                                                 | About the same                                                        |
| Does utilization management delay patient access                                               | Sometimes                                                             |
| In your experience, patient out-of-pocket costs for this drug are                              | Similar                                                               |



|                                                                                                                          |                                                                                                                                                                                                                                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Have patients delayed or declined treatment due to cost?</b>                                                          | Occasionally                                                                                                                                                                                                                                                                                                                         |
| <b>Impact of patient cost on adherence</b>                                                                               | Moderate impact                                                                                                                                                                                                                                                                                                                      |
| <b>Are there other impacts that cause adherence issues?</b>                                                              | Yes, there are multiple other factors beyond cost that cause adherence issues with Verzenio. The most significant non-cost barriers include side effects (particularly diarrhea), forgetfulness, inadequate patient-provider communication, psychological distress, and patient-specific factors such as age and regimen complexity. |
| <b>Availability of the drug when clinically needed</b>                                                                   | Routinely available                                                                                                                                                                                                                                                                                                                  |
| <b>If delays occur, primary cause</b>                                                                                    | Payer authorization                                                                                                                                                                                                                                                                                                                  |
| <b>Overall impact of this drug on health system costs</b>                                                                | Increases costs substantially                                                                                                                                                                                                                                                                                                        |
| <b>Overall value of this drug relative to its cost</b>                                                                   | Moderate value                                                                                                                                                                                                                                                                                                                       |
| <b>From a clinical perspective, does this drug contribute to affordability concerns for patients?</b>                    | Yes                                                                                                                                                                                                                                                                                                                                  |
| <b>Is there anything else you would like PDAB to know about this medication?</b>                                         | No.                                                                                                                                                                                                                                                                                                                                  |
| <b>If you could change one thing about how this prescription drug is priced or accessed in Oregon, what would it be?</b> | A state-required cap on out-of-pocket costs for oral cancer drugs like Verzenio would likely have the biggest positive effect on patient access in Oregon. It would help reduce cost barriers throughout the year while still supporting a more sustainable system.                                                                  |